DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Saturday 5 July 2014

Interpreting a NMR Spectrum


Interpreting a NMR Spectrum
The following 1Hnmr spectrum of a C10H12O2 compound was obtained on a 90 MHz spectrometer.
The 1Hnmr spectrum of the unknown C10H12O2 compound is shown above. Seven structural formulas of some possible candidates for this compound are presented below. After reviewing the chemical shifts, coupling patterns and integration values shown in this spectrum, select the structure most likely to give this spectrum,  ( A through G ) 
THE FOLL POINTS WILL HELP YOU
 
1.  Ignoring the TMS signal at δ = 0, how many discrete groups of proton signals are present in this spectrum?

2.  What is the multiplicity ( sdtq ) of the highest field signal from this sample?

3.  The sample has a singlet at δ = 3.8 ppm. In units of Hertz (Hz) how far is this signal from the TMS signal?
4.  What structural feature is suggested by the singlet at δ = 3.8 ppm?
          A CH3–C=O     B –CH2–     C –O–H     D –O–CH3     E C–CH3     F C=C–H 

5.  From multiplet line separations (Js), which of the other signals is coupled to the quartet at δ = 2.9 ppm?
          A δ = 1.2 ppm     B δ = 3.8 ppm     C δ = 6.9 ppm     D δ = 7.9 ppm


6.  Using the integrator trace and the formula of the sample, assign a whole number ratio to the sample signals as follows:
          7.9 ppm signal ;     6.9 ppm signal ;     3.8 ppm signal ;     2.9 ppm signal ;     1.2 ppm signal 
 
 
 
 
Structure Analysis

The compound's formula, C10H12O2, has less hydrogen than decane (C10H22). The difference of 10 hydrogens suggests the presence of five double bonds and/or rings in the structure. Since a benzene ring has three double bonds and one ring, and the nmr signals at δ = 7.9 and 6.9 ppm are consistent with aryl hydrogen resonances, we conclude that this compound has a benzene ring.

Integration indicates the presence of two methyl groups, a O–CH3 at δ = 3.8 ppm, and a C–CH3 at δ = 1.2 ppm. The former is of course a singlet, but the latter is a triplet (J = 8 Hz) due to coupling with a –CH2– moiety, which in turn is split into a quartet (signal at δ = 2.9 ppm). From the chemical shifts, we conclude there is an ethyl group bonded to an sp2 hybrid carbon atom.

If we examine the structural formulas of the seven candidate compounds, we can eliminate A, C, F & G because they do not have a –O–CH3 group and cannot account for a singlet at δ = 3.8 ppm. Structure D does not have an ethyl group, so we are left with B & E as the most likely source of this spectrum.

It is not a simple job to distinguish B & E by 1Hnmr alone. The simplicity of the aromatic proton region indicates para-disubstitution of the benzene ring. If the two substituents are similar in nature, the ring proton signals would have similar chemical shifts. If the substituents are very different in nature, these signals would also have significantly different chemical shifts. Since the aromatic doublets in this spectrum are separated by 90 Hz (1.0 ppm), we may tentatively select E (oxygen and carbon substituents) over B (two different carbon substituents).

A better means of distinguishing these compounds is by infrared spectroscopy. Ester carbonyl stretching frequencies are usually higher than equivalent ketone frequencies by roughly 25 cm-1. Also the 13Cnmr carbonyl signal from esters (δ = ca. 170 ppm) is usually observed at higher field than ketone carbonyl signals (δ = ca. 200 ppm).
The spectrum is in fact that of E.


1H NMR
13 C NMR


IR


















shark






DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com









No comments:

Post a Comment